Log in

NASDAQ:ACERAcer Therapeutics Stock Price, Forecast & News

Add
Compare
Today's Range N/A
50-Day Range
$3.11
MA: $3.48
$4.47
52-Week Range N/A
Volume3.02 million shs
Average Volume370,560 shs
Market Capitalization$55.45 million
P/E RatioN/A
Dividend YieldN/A
Beta1.82
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes three clinical-stage candidates: EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; and ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders, maple syrup urine disease, and osanetant for the treatment of various neuroendocrine disorders. The company was founded in 2013 and is headquartered in Newton, Massachusetts.
Read More
Acer Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.93 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ACER
CUSIPN/A
Phone844-902-6100

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.82 per share

Profitability

Net Income$-29,420,000.00

Miscellaneous

Employees23
Market Cap$55.45 million
Next Earnings Date8/11/2020 (Estimated)
OptionableNot Optionable
30 days | 90 days | 365 days | Advanced Chart

Receive ACER News and Ratings via Email

Sign-up to receive the latest news and ratings for ACER and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Acer Therapeutics (NASDAQ:ACER) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Acer Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acer Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Acer Therapeutics
.

When is Acer Therapeutics' next earnings date?

Acer Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020.
View our earnings forecast for Acer Therapeutics
.

How were Acer Therapeutics' earnings last quarter?

Acer Therapeutics Inc (NASDAQ:ACER) announced its earnings results on Thursday, May, 14th. The biopharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.40) by $0.09.
View Acer Therapeutics' earnings history
.

What price target have analysts set for ACER?

3 analysts have issued 12 month target prices for Acer Therapeutics' shares. Their forecasts range from $10.00 to $10.00. On average, they anticipate Acer Therapeutics' share price to reach $10.00 in the next twelve months.
View analysts' price targets for Acer Therapeutics
.

Has Acer Therapeutics been receiving favorable news coverage?

Media stories about ACER stock have been trending extremely negative recently, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Acer Therapeutics earned a media sentiment score of -4.8 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future.
View the latest news about Acer Therapeutics
.

Are investors shorting Acer Therapeutics?

Acer Therapeutics saw a decline in short interest during the month of July. As of July 31st, there was short interest totaling 350,300 shares, a decline of 7.5% from the July 15th total of 378,800 shares. Based on an average daily trading volume, of 270,600 shares, the days-to-cover ratio is currently 1.3 days. Currently, 6.8% of the shares of the company are short sold.
View Acer Therapeutics' Short Interest
.

Who are some of Acer Therapeutics' key competitors?

What other stocks do shareholders of Acer Therapeutics own?

Who are Acer Therapeutics' key executives?

Acer Therapeutics' management team includes the following people:
  • Mr. Christopher Schelling, Founder, Pres, CEO & Director (Age 43)
  • Mr. Harry S. Palmin, COO & CFO (Age 49)
  • Dr. William T. Andrews M.D., FACP, Chief Medical Officer (Age 54)
  • Mr. Donald R. Joseph, Chief Legal Officer & Sec. (Age 65)
  • Ms. Jeannie Kim, VP of Corp. Devel.

What is Acer Therapeutics' stock symbol?

Acer Therapeutics trades on the NASDAQ under the ticker symbol "ACER."

How do I buy shares of Acer Therapeutics?

Shares of ACER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

How big of a company is Acer Therapeutics?

Acer Therapeutics has a market capitalization of $0.00. The biopharmaceutical company earns $-29,420,000.00 in net income (profit) each year or ($2.91) on an earnings per share basis. Acer Therapeutics employs 23 workers across the globe.

What is Acer Therapeutics' official website?

The official website for Acer Therapeutics is www.acertx.com.

How can I contact Acer Therapeutics?

Acer Therapeutics' mailing address is 300 WASHINGTON STREET SUITE 351, NEWTON MA, 02458. The biopharmaceutical company can be reached via phone at 844-902-6100 or via email at [email protected]

This page was last updated on 8/9/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.